Preclinical investigations have provided evidence of a synergistic antitumor effect in humanized mice bearing melanoma tumors treated with ONCOS-102 in combination with pembrolizumab, which can be explained by the capacity of the virus to trigger an immunogenic cancer cell death that subsequently supports the activation of T cells by pembrolizumab by suppressing the PD-1/PD-L1 interaction (118, 119). Here, CD274 is linked to cancer.